Nabilone is a prescription medication commonly used to provide supportive therapeutic benefit by moderating distressing symptoms across several key clinical domains, primarily in patients who have not responded adequately to conventional treatments.

---

Key Therapeutic Domains

This medication is relevant in contexts involving heightened systemic burden and plays a role in managing: severe nausea and vomiting associated with chemotherapy (CINV), adjunctive support for chronic, complex pain (such as neuropathic pain and spasticity-related pain), and support for appetite loss linked to wasting syndromes. It is generally applied in clinical settings marked by acute or unstable symptom patterns.

“Nabilone is commonly used when symptoms intensify and supportive relief is needed, assisting patients during episodes of heightened discomfort.”

The benefit may provide support that helps patients cope more steadily with difficult episodes, contributing to the easing of functional strain and discomfort caused by these disruptive symptom manifestations.

Quick Fact: Relief for Refractory Symptoms
Nabilone is often used in conditions characterized by periods of heightened symptoms and is relevant when symptoms become temporarily overwhelming or have not responded adequately to initial therapies.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Nabilone?

The population eligibility for Nabilone is strictly defined by regulatory documents, focusing on patient age, reproductive status, co-existing medical conditions, and known sensitivities.

Eligibility Scope	Official Regulatory Statement
Populations Allowed	Adult patients (18 and older) who have failed to respond adequately to conventional antiemetic treatments for severe nausea and vomiting associated with cancer chemotherapy.
Absolute Contraindications	Patients with a known hypersensitivity to Nabilone or any other cannabinoid agent; patients with a history of psychotic reactions [1.6, 1.7].
Not Recommended/Not Established	Children/Pediatric patients (under 18 years) as safety and efficacy have not been established; breastfeeding mothers [1.7, 2.3].

Condition-Specific Eligibility Restrictions

Nabilone must be used with explicit caution, special consideration, or under close supervision in the following groups, as directed by official labeling:

• Severe Liver Impairment: Must be used with extreme caution [1.7].
• Psychiatric Disorders: Use with caution in patients with a history of psychiatric disorders (e.g., depression, schizophrenia) [1.4].
• Cardiovascular Conditions: Use with caution in patients with hypertension or heart disease due to potential cardiac effects [1.4, 1.7].
• The Elderly: Use with caution, as older adults may be more susceptible to effects like postural hypotension [1.4].

Pregnancy and Lactation Eligibility

Regulatory documents advise use during pregnancy only if clearly needed and not recommended for nursing mothers [1.7, 2.3].

Interactions with other medicines and products

The interaction profile for nabilone is characterized primarily by pharmacodynamic effects on the central nervous system (CNS) and cardiovascular system, as documented in regulatory information.

Contraindicated Combinations

• Nabilone is formally contraindicated in any patient with a known history of hypersensitivity or allergic reaction to any cannabinoid agent, which includes nabilone itself.

Pharmacodynamic Interactions

Product Category	Official Description of Effect
CNS Depressants (e.g., sedatives, hypnotics, opioid analgesics, barbiturates)	The simultaneous use results in additive or synergistic depressant effects on CNS function. Studies specifically documented additive effects with diazepam and sodium secobarbital.
Alcohol	Must not be taken with nabilone, as the combination produces additive depressive effects on CNS function.
Anticholinergic Agents	Potential for additive or super-additive anticholinergic effects, such as tachycardia and increased drowsiness.
Cardiovascular Agents	Caution is necessary when co-administering with sympathomimetic agents or antihypertensive drugs due to the potential for nabilone to cause tachycardia and orthostatic hypotension.

Pharmacokinetic Interactions

• In in vitro studies, nabilone demonstrated weak to moderate inhibitory effects on CYP450 enzymes (CYP2E1, CYP3A4, CYP2C8, and CYP2C9).
• However, official regulatory information states that the very low nabilone plasma concentration achieved in clinical use is unlikely to interfere with the P450-mediated metabolism of co-administered drugs.

Population-Specific Interaction Notes

• Elderly patients should be managed with caution due to the potential for increased sensitivity to CNS and cardiovascular effects.
• Nabilone should be used with extreme caution in patients with severe liver dysfunction, as the primary elimination pathway is the biliary system.

Primary Mechanism: Central Cannabinoid Receptor ( CB1) Agonism

Nabilone is a synthetic cannabinoid that acts as an agonist (activator) at the cannabinoid receptor type 1 ( CB1), a G-protein coupled receptor highly expressed in the central nervous system. This action initiates the core mechanistic cascade by engaging mechanisms that modify signal transduction within relevant neural pathways.

---

Modifying Signal Transduction in Brainstem Nuclei

The primary mechanism results in the CB1-mediated inhibition of neurotransmitter release within key brainstem nuclei involved in emetic regulation. This modulation of early molecular steps results in the reduction of mediator activity, thereby altering the signal transduction dynamics within the targeted pathways.

---

Engaging the Endocannabinoid Regulatory Systems

Nabilone also engages with the broader endocannabinoid system, including interaction with cannabinoid receptor type 2 ( CB2) and other related signaling mechanisms. This broad action influences signaling mechanisms and receptor activity, resulting in changes to defined signaling patterns and alterations of physiological regulation in central and peripheral pathways.

How to Use Nabilone: Administration Guidelines

Nabilone is administered as an oral capsule and must be swallowed whole, without being opened or crushed. The usage guidelines outline a specific, time-limited regimen that is structured around the chemotherapy cycle.

Standard Dosing and Frequency

Feature	Instruction
Route of Administration	Oral, as a hard gelatin capsule.
Dosing Schedule	The usual starting adult dose is 1 mg or 2 mg per dose. The dose may be adjusted, but the daily maximum is 6 mg in divided doses.
Frequency	Typically taken two or three times a day in divided doses, with prescriptions often limited to the amount needed for a single cycle of chemotherapy.
Timing with Meals	Nabilone can be administered with or without food.

Use Patterns and Population Rules

Administration is generally prophylactic (preventative) and follows a fixed schedule, rather than being used on an as-needed basis. The first dose is intended to be taken 1 to 3 hours before the start of the chemotherapeutic agent; a dose may also be given the night before. Dosing may continue throughout the treatment cycle and for up to 48 hours after the last dose of chemotherapy.

Population-Specific Guidance: For older adults, dosing should be initiated cautiously at the lower end of the recommended dosage range. The medication is generally not recommended for use in children under 18 years old or in patients with severe liver dysfunction. If central nervous system effects occur, a subsequent dose may be withheld, and routine dosing should only be resumed at a lower amount after symptoms resolve.

Research Evidence / Overview of Studies for Nabilone

---

Evidence for Severe Nausea and Vomiting Associated with Chemotherapy (Refractory CINV)

Research exploring this use relies on Randomized Controlled Trials (RCTs) and systematic reviews, focusing on patients with severe symptoms that had not responded adequately to initial, conventional antiemetic treatments. Studies were designed to neutrally monitor differences in the measurement of nausea and vomiting severity and frequency between the Nabilone and placebo groups. Some trials reported measurements observed across Nabilone and older, conventional antiemetic drug comparator groups. The regulatory process for the specific indication relies on the trial findings involving patients failing to respond adequately. Research does not provide comparative data against the current standard-of-care antiemetic treatments, and long-term effects are not fully established.

---

Evidence for Chronic Non-Cancer Pain

The evidence for chronic pain, which includes conditions like neuropathic pain and fibromyalgia, has been evaluated in systematic reviews and meta-analyses compiling data from various smaller RCTs. These studies monitored patient-reported outcomes describing perceived discomfort, such as pain intensity assessed via numerical scales, and functional outcomes related to sleep quality. Findings were mixed across studies; some aggregated data reported measurements where the observed patterns of pain intensity were studied against placebo groups, while other studies reported no difference. Follow-up durations were limited, with most trials lasting only a few weeks to a few months.

---

What is Still Uncertain About Nabilone Research

The research base includes limitations such as the varied results noted across different pain studies and the use of older comparators in CINV research. The vast majority of the research was conducted primarily within adult populations, and data for children, adolescents, and complex comorbidities remain insufficient. Study results reflect the specific conditions and group patterns under which they were conducted, not individual predictions. Evidence is limited for long-term use, and a consensus remains that future research should examine longer follow-up durations and larger sample sizes.

Key Studies & References

1. Cannabinoids for the treatment of chronic non-cancer pain: a systematic review and meta-analysis of randomized controlled trials
2. Therapeutic potential of Nabilone in chronic non-cancer pain, a systematic review

Common questions about Nabilone (FAQ)

Q: How quickly does Nabilone start to work after taking it?

The official documentation states that the onset of the psychoactive effects for Nabilone is typically within approximately two hours after a single oral dose. This timeframe reflects how the medication is processed by the body and how quickly it begins to act on the central nervous system.

Q: How long do the effects of Nabilone typically last?

The active breakdown products (metabolites) of Nabilone have a long half-life, which contributes to sustained effects. Official product information states that the elimination half-life of the active metabolites is around 35 hours.

Q: What is the difference between Nabilone and Dronabinol?

Nabilone and Dronabinol are both described in regulatory documents as synthetic cannabinoid medicines, but they have distinct chemical structures. Nabilone is described as a synthetic analogue of Delta^9-THC, while Dronabinol is synthetic Delta^9-THC itself. Regulatory documents indicate they are approved for different primary clinical indications.

Q: Does taking Nabilone affect driving or operating machinery?

Official safety guidance warns that Nabilone can impair mental and physical abilities. For this reason, official safety information describes restrictions on driving or operating machinery and performing hazardous tasks until individuals are certain the drug does not cause adverse effects like dizziness or drowsiness.

Q: Is it possible to develop a tolerance to Nabilone?

Regulatory documents note that tolerance can rapidly develop to some of the common Central Nervous System (CNS) effects. This includes effects such as relaxation, drowsiness, and euphoria, and official information indicates that this tolerance is easily reversed.

Q: What should I do if I forget to take a dose of Nabilone?

Official regulatory guidance describes how to proceed if a dose is missed. This guidance involves taking the dose if the lapse is remembered soon after, or skipping it if it is nearly time for the next dose. Regulatory guidance further states that doses should not be doubled.

Q: Does Nabilone have withdrawal effects if stopped suddenly?

Nabilone is classified as a controlled substance due to the potential for abuse and psychological dependence. Regulatory labeling describes the potential for adverse psychiatric reactions upon abrupt discontinuation, which can persist for up to 48 to 72 hours.

Q: What type of monitoring is needed while taking Nabilone?

Official regulatory documents advise that patients should be monitored by their healthcare provider for certain effects. This includes monitoring for Central Nervous System (CNS) effects like dizziness or changes in mental status, signs of abuse or misuse, and cardiovascular changes such as fast heart rate (tachycardia) and a drop in blood pressure upon standing (orthostatic hypotension).

Q: Does Nabilone interact with common antidepressant drugs?

Caution is officially advised regarding the use of Nabilone with any other medication that affects mental function or causes CNS depression. This category of medicines can include certain types of common antidepressant drugs due to the potential for combined or additive depressant effects.

Q: Is Nabilone used for conditions like multiple sclerosis?

The primary official approved use for Nabilone is for severe chemotherapy-induced nausea and vomiting. While research has examined its use for symptoms in conditions like multiple sclerosis (MS), the official documentation states that this is not an an approved primary indication for the drug.

Q: Is Nabilone safe to use if I have kidney problems?

Regulatory guidance addresses the use of Nabilone in individuals with kidney impairment. Official product information indicates that a dose adjustment related to renal (kidney) impairment is generally not necessary.

Q: Can Nabilone affect the results of a drug test?

As Nabilone is a synthetic compound chemically related to Delta^9-THC, the active psychoactive component of cannabis, regulatory information indicates that Nabilone may interfere with drug screenings for cannabinoids.

Q: Does Nabilone impact fertility?

Studies conducted in animals, as described in official product information, have not shown an effect on fertility or reproductive performance, even when using doses significantly higher than those given to humans.

Nabilone capsules must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F to 86 F). The medication requires protection from light, excess heat, and moisture; therefore, storage in environments like a bathroom is not recommended. The capsules must remain in the container it came in and be kept tightly closed.

As a controlled substance, Nabilone must be stored in a safe, secure place and kept strictly out of the sight and reach of children to prevent accidental ingestion or misuse. All safety caps must be locked. Unused or expired medication must be properly discarded according to official instructions, which generally involves consulting a pharmacist or local waste disposal company rather than flushing or using household trash.